iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces that on Friday February 15, 2019 the Company delivered written notice terminating, with immediate effect, its product sublicense agreement with Immune Pharmaceuticals (IMNP: OTCQB), related to iCo-008 (Bertilimumab). Subsequent to the above noted termination, Immune Pharmaceuticals filed a voluntary petition for bankruptcy in the District of New Jersey on February 17, 2019.
